Abstract PO1-28-07: Neoadjuvant docetaxel plus cisplatin versus docetaxel plus doxorubicin and cyclophosphamide in early-stage triple-negative breast cancer (HNBC-001): results from a multicenter, randomized controlled, open-label phase II trial
Dechuang Jiao(Zhengzhou University), Zhenzhen Liu(Zhengzhou University), Miao Deng(Sichuan University), Haiquan Jia(Anyang Tumor Hospital), Qingxin Xia(Zhengzhou University), Xianfu Sun(Henan Cancer Hospital), Min Yan(Zhengzhou University), Chengzheng Wang(Henan Cancer Hospital), Lianfang Li(Henan Cancer Hospital), Xinlan Liu(Yunnan Agricultural University), Yong Zhou(Xinjiang Medical University), Jianghua Qiao(Henan Cancer Hospital), Juntao Li(Capital Medical University), Yueqing Feng(Xinxiang Central Hospital), Zhenduo Lu(Zhengzhou University), Xiuchun Chen(Henan Cancer Hospital), Mingde Ma(Henan University Huaihe Hospital and Huaihe Clinical Institute), Chongjian Zhang(Zhengzhou University)
Cited by 0
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway
|Oncotarget|2017|400
miR-126 functions as a tumour suppressor in human gastric cancer
|Cancer Letters|2010|298
Induction of Pyroptosis and Its Implications in Cancer Management
|Frontiers in Oncology|2019|274
CD36 mediates palmitate acid-induced metastasis of gastric cancer via AKT/GSK-3β/β-catenin pathway
|Journal of Experimental & Clinical Cancer Research|2019|231